Consegna Pharma Wins PhI & PhII NIH SBIR Awards

IPart has assisted Consegna Pharma Inc. with a number of their SBIR proposals.  This year (2023), Consegna was successful in winning a PhI SBIR from NIH for $326,500 and a PhII, also from NIH for $2,550,000.

Consegna is a specialty pharmaceutical company that reformulates known, safe drugs and creates long-acting injectable (LAI) medications with improved clinical and economic benefits. These long-acting drug formulations enable a single administration to provide a therapeutic effect ranging from several days to many weeks or months. Our product pipeline focuses on therapeutic areas with high non-adherence, or where LAIs can solve specific drug delivery challenges. Using our Computational Drug Delivery™ technology, we can design LAIs much faster than the legacy practice and with reduced regulatory and technical risk. We take advantage of the accelerated 505(b)(2) FDA regulatory pathway by focusing on off-patent medications.

Consegna Pharma used IPart Preferred Provider BBC Etc. as the IPart MicroVoucher Consultant for their PhI proposal submission and Brooks Consulting for their PhII IPart FMA.

Pennsylvania’s Innovation Partnership (IPart) is supported by an SBA FAST Award & the financial and staff counseling contributions of our IPart Partner Organizations